BD buys reagent-maker Sirigen Group; J&J recalls discontinued custom implants;

 @FierceMedDev: It's a good day to be CardioDx. The company pulled in $58M in new financing. News | Follow @FierceMedDev

 @MarkHFierce: Cook Medical opens a new plant today in Illinois. Article | Follow @MarkHFierce

 @DamianFierce: The first wave of renal denervation devices have impressed docs in the EU. Report | Follow @DamianFierce

> Becton, Dickinson and Company ($BDX), a medical devices, instrument and reagent manufacturer, has snatched up Sirigen Group, a manufacturer of "unique polymer dyes." Neither side disclosed financial terms. Release

> Sophono, a Boulder, CO-based maker of implantable, bone conduction hearing devices, has raised $7 million in new financing. Item

> Maquet Cardiovascular generated mixed results in a clinical trial involving its intra-aortic balloon counterpulsation therapy for heart attack patients. Release

> Medtronic ($MDT) released the results of a long-term safety study of its drug-eluting stents, finding low rates of blood clot formation in patients treated for coronary artery disease. More

> Johnson & Johnson's ($JNJ) DePuy Orthopedics unit has recalled all of its unused custom implants, a business it discontinued in January. News

> Blockade Medical said it has treated the first patients with its Barricade Coil System, a device designed to treat cerebral aneurysms. Release

> HeartFlow says a new study shows its fractional flow reserve technology, used with CT angiography, more accurately determines which patient's blocked arteries need surgical attention than when using CT alone. Release

Biotech News

 @FierceBiotech: Analysis: For Eli Lilly's solanezumab, take 2 doesn't look so pretty. More | Follow @FierceBiotech

 @JohnCFierce: FDA wants a rewrite on Lemtrada app? Bit of an embarrassment for Genzyme and its overseers at Sanofi. Report | Follow @JohnCFierce

 @RyanMFierce: Ex-Google guys eye clinical trials with startup Flatiron. Story | Follow @RyanMFierce

> Merck readies apps for two cardio drugs. Article

> Promising T-DM1 clears PhIII cancer study and marches on to the FDA. Story

> Idenix plunges after FDA puts another hep C treatment on hold. News

> ESC Round-up: Head-to-head flop for Eli Lilly, PhII bonus for Novartis cardio drug. More

Pharma News

 @FiercePharma: Interested in the new GSK site at Philly's Navy Yard? 22 pics of construction in progress--via Philadelphia Business Journal. Gallery | Follow @FiercePharma

> Roche makes a tax deal on doomed Nutley site. More

> Lilly's Effient hopes dashed by head-to-head Plavix trial. Article

> Hospira adding 200 jobs at NC plant. News

> No more bids for Par Pharma, so $1.9B deal with TPG stands. Report

Biotech IT News

> Groups craft algorithms to rank drug contenders. Story

> Sanofi takes wisdom of crowd in social media blitz. Item

> Ex-Google guys eye clinical trials with startup Flatiron. News

> Amazon targets pharma R&D, others with new cloud storage. More

> Boehringer sets launch date for pharma's first social game on Facebook. Article

CRO News

> Chinese CRO Tigermed completes $80M IPO. Item

> West to open CMO facility in India. Story

> Pfizer backs out of generics deal with India's Claris. News

> PRA expands its Chinese presence as market swells. Article

> Researchers bristle at India's proposed trial reforms. Story

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.